2.  91.7% of respondents (343 out of 374) have a DEA
waiver to prescribe buprenorphine for at least 30
patients
 73.3% are waivered to treat 100 patients
 43.8 % of respondents indicated they have demand for
buprenorphine treatment that exceeds the 100 patient
limit

3. 6.3%
30.4%
10.1%
7.4%
15.5%
30.4%
0% 5% 10% 15% 20% 25% 30% 35%
More than 100
81-100
61-80
41-60
21-40
Fewer than 20
The Number Patients per Month for whom
Respondents Currently Prescribe Buprenorphine for
theTreatment of Opioid Dependence

4. 2.8%
62.8%
8.9%
10.0%
23.1%
18.3%
0% 10% 20% 30% 40% 50% 60% 70%
Other*
None of the above
All of the above
CertifiedAddictions Registered Nurses
(CARN)
Nurse Practitioners
Physicians'Assistants
Percent of Respondents Who FeelThis Group Should be
Allowed to Apply for and Obtain a Waiver to Prescribe
Buprenorphine for theTreatment of Opioid Addiction
*Other comments include: lifting 100 patient limit for ABAM certified
physicians, requiring supervision for above groups to prescribe.

5.  19.8% of respondents order or prescribe
medications for the treatment of opioid dependence
in/from a federally-approved OTP
 79.5% of these order methadone
 57.3% order or prescribe buprenorphine
 Most respondents indicated that states impose
requirements – such as time in treatment or
compliance with diversion control programs – in
order for patients to gain take-home privileges for
buprenorphine

6.  38.7% of respondents prescribe extended release
naltrexone for opioid dependent patients
 The vast majority of patients (62.2%) receive
their injection in a private office setting

7. 15.0%
8.3%
10.5%
66.2%
0% 10% 20% 30% 40% 50% 60% 70%
More than 15
11-15
6-10
1-5
The Number of Patients for whom Respondents
Currently Prescribe Extended Release Naltrexone

8.  55.4% of respondents prescribe oral naltrexone
for opioid dependent patients